新冠病毒SARS-CoV-2 Spike RBD重组蛋白

SARS-CoV-2 (2019-nCoV) Spike RBD-AVI & His Recombinant Protein, Biotinylated: 产品信息
纯度> 95 % as determined by SDS-PAGE.

内毒素< 1.0 EU per μg protein as determined by the LAL method.
生物活性Measured by its binding ability in a functional ELISA. Immobilized human ACE2 protein (Fc tag)(10108-H05H) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 (2019-nCoV) Spike RBD-AVI & His Recombinant Protein, Biotinylated(40592-V27B-B),the EC50 of SARS-CoV-2 (2019-nCoV) Spike RBD-AVI & His Recombinant Protein, Biotinylated (40592-V27B-B) is 17-40 ng/mL.

蛋白构建A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (RBD) (YP_009724390.1) (Arg319-Phe541) was expressed with a c-terminal polyhistidine tagged AVI tag at the C-terminus. The purified protein was biotinylated in vitro.
表达宿主Baculovirus-Insect Cells
种属2019-nCoV
预测 N 端Arg319
分子量The recombinant SARS-CoV-2 (2019-nCoV) Spike Protein (RBD) consists of 249 amino acids and predicts a molecular mass of 28.36 kDa.
缓冲液Lyophilized from sterile 20mM PB, 300mM NaCl, 5% glycerol, pH 7.0
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
运输方式In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
稳定性 & 储存条件Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
 
北京义翘神州科技股份有限公司（Sino Biological Inc.）创建于2007年，是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务。



义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务，能够覆盖生命科学研究的多个领域，为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供“一站式”生物试剂产品和技术服务。客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲等地建立了子公司，在上海建立分公司，已成为生物试剂行业国内领先的科技公司之一。



凭借多年病毒蛋白研究技术优势，义翘神州仅用11天就成功表达出新冠病毒重要靶点受体结合域蛋白。为了更好的支持新冠病毒研究，义翘神州已开发生产近百种新冠病毒相关科研试剂，包括重要靶点抗原蛋白、中和抗体、抗原蛋白检测试剂盒等。义翘神州还可以提供新冠假病毒中和检测服务，可用于筛选出具有中和活性的抗体或血清，支持在细胞水平上的评估。目前，这些科研试剂已被全球数百家研究机构用于疫苗和抗体开发及基础机制研究。